Prevention of Docetaxel Induced Dacryostenosis

Status Completed

Clinical Trial Summary

The antineoplastic agent Docetaxel (Taxotere®) is approved for the treatment of patients with metastatic and locally advanced breast cancer and other malignancies. There are 2 frequently used schedules of treatment with Docetaxel. Docetaxel can be administered every 3 weeks or in a weekly regimen. The efficacy seems to be similar but the toxicity profile changes. In the standard 3-weekly Docetaxel regimen the dose-limiting side effect is myelosuppression, while in the weekly regimen there is only a mild myelosuppression. On the other hand, weekly Docetaxel has a side effect that is rare in the 3-weekly schedule: epiphora (= tearing eye) caused by dacryostenosis.

The underlying mechanism of dacryostenosis induced by weekly Docetaxel is fibrosis of the lacrimal puncta and canaliculi. Docetaxel has been reported to be secreted in the lacrimal tears. Direct contact between Docetaxel containing tears and the epithelial lining causes chronic inflammation of the mucosa and ultimately fibrosis of the most narrow part of the lacrimal outflow system i.e. the lacrimal puncta and canaliculi.

A surgical treatment is possible for dacryostenosis. In case of subtotal stenosis of the lacrimal canaliculi, silicone intubation of the canaliculi is performed in order to prevent further closure. In the case of complete stenosis, placement of a permanent pyrex glass tube of Jones is required.

To our knowledge, there is no primary prevention for Docetaxel induced dacryostenosis.

The rationale of this randomized double blind interventional study is to investigate the efficacy of corticosteroid versus artificial tears topical eye treatment in patients on a weekly Docetaxel regimen in prevention of dacryostenosis. The dacryotoxic agent Docetaxel in the lacrimal tears will be washed away by the repetitive use of eye drops. In addition, eye drops containing corticosteroids have an anti-inflammatory effect and may further prevent the formation of fibrosis.

A new treatment protocol will be investigated. Two different commercially available eye drops will be compared: dexamethasone sodium phosphate (Maxidex®, Alcon) in one eye of the patient and artificial tears (Lacrystat®, Viatris) in the other eye of the same patient. The study period will start with topical eye treatment from day 1 of cycle 1 and will continue during the administration of chemotherapy, with a final analysis at 26 weeks.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

Epiphora

Clinical Trial Details

NCT number	NCT00266838
Study type	Interventional
Source	Universitaire Ziekenhuizen Leuven
Contact
Status	Completed
Phase	Phase 1
Start date	July 2006
Completion date	May 2009

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04833452` - Comparative Study Between Wide and Narrow Fenstrum Endoscopic DCR	N/A
Completed	`NCT02240615` - The Sinopsys Lacrimal Stent for Lacrimal System Repair in Epiphora	Phase 0
Suspended	`NCT03705000` - SLlt Stent II Lacrimal Stent for the Treatment of Nasolacrimal Duct Obstruction	N/A
Completed	`NCT01010659` - The Safety and Efficacy of Lacrimal Silicone Intubation for the Management of Epiphora	Phase 4
Recruiting	`NCT05663684` - Does Topical Ophthalmic Proparacaine 0.5% Prior to Probing and Irrigation Decrease Pain?	Phase 4
Terminated	`NCT04229771` - Does Topical Ophthalmic Anesthetic Prior to Probing and Irrigation Decrease Pain?	Phase 4
Active, not recruiting	`NCT02849093` - Optical Coherence Tomography of Ocular Structures in Epiphora and Dry Eye Syndrome.	N/A
Withdrawn	`NCT00824811` - Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel	Phase 2
Completed	`NCT03731143` - Management of Lower Punctal Stenosis.	N/A
Active, not recruiting	`NCT04680078` - Placement of Three Interrupted Sutures After Triangular Three-snip Punctoplasty	N/A
Completed	`NCT01282541` - Determination of the Optimum Delivery Route for Botulinum Toxin A in Patients With Epiphora	Phase 2
Completed	`NCT02503956` - Perforated Punctal Plugs for Treatment of Papillary Conjunctivitis in Otherwise Healthy Patients	N/A
Completed	`NCT04637633` - Topical Cyclosporine-A for Management of Epiphora	Phase 2/Phase 3
Withdrawn	`NCT03266081` - Bupivacaine Epiphora Trial	Phase 2
Completed	`NCT01766232` - Lacrimal Drainage Resistance Study	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.